cryptocurrency and- Top snippets

The turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 15.6 billion yuan more than the previous day. Up to now, the turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 15.6 billion yuan more than the previous day. Among them, the turnover of Shanghai Stock Exchange was 378.3 billion yuan, that of Shenzhen Stock Exchange was 611.9 billion yuan, and that of Beizheng 50 was 10.5 billion yuan.The Chinese medicine sector collectively pulled up Panlong Pharmaceutical's linear daily limit, Panlong Pharmaceutical's linear daily limit, Xiangxue Pharmaceutical, Kunyao Group, Huasen Pharmaceutical, Jingxin Pharmaceutical, Xinguang Pharmaceutical and Changyao Holdings followed suit.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.

Survey: More than 40% of analysts expect the Bank of Japan to raise interest rates this month, but most think that January next year is the best time. According to the latest survey, observers of the Bank of Japan predict that January is the most likely time to raise interest rates next time, but more than 40% of the respondents still expect to take action next week. According to the survey, about 52% of the 52 economists surveyed expect the Bank of Japan to raise the policy interest rate from 0.25% in January, compared with 32% in the last survey. About 44% of the respondents expect the central bank to take action at the end of the two-day meeting on December 19, down from 53% in the last survey. The survey results show that observers believe that the Bank of Japan's policy meeting this month is likely to move or not to move to a large extent. About 88% of the respondents said that the earliest possible time to raise interest rates in their risk scenarios is next week. Another equally high data shows that Japan's economic and price environment will justify raising interest rates this month.Zhangjiakou Smart Grid Auto Equity Investment Fund was registered and established. The enterprise search APP shows that recently, Zhangjiakou Smart Grid Auto Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 301 million yuan. Its business scope includes: engaging in equity investment, investment management and asset management with private equity funds. Enterprise investigation shows that the company is jointly owned by Zhangjiakou Industrial Investment Holding Group Co., Ltd. and Zhangjiakou Nanshan Economic Development Zone Construction and Development Co., Ltd.The securities sector fluctuated and strengthened, and the securities sector fluctuated and strengthened. Guosheng Financial Holdings had three consecutive boards, Guolian Securities rose more than 8%, and Harbin Investment Co., Ltd., Huaxin Co., Ltd., Cinda Securities and Southwest Securities followed suit.

People's Government of Minhang District, Shanghai: Helping enterprises to go out and encourage foreign trade enterprises to expand their business. The People's Government of Minhang District issued the Policy Opinions on High-quality Industrial Development in Minhang District (Trial), which pointed out that helping enterprises to go out. Support enterprises to purchase export credit insurance products and build or rent overseas warehouses overseas. Encourage foreign trade enterprises to expand their business and give certain financial support to enterprises that reach a certain scale. Support new energy vehicles, used cars, photovoltaics and other enterprises to expand overseas markets. Support the development of cross-border e-commerce. Support the development, maintenance and system construction of enterprises to build or dock cross-border e-commerce platforms. Encourage enterprises to export business in cross-border e-commerce mode. Encourage enterprises to deeply participate in the creation of the "Silk Road E-commerce" cooperation pioneer zone.Baijiayun received $15 million in financing. One-stop AI video technology service provider Baijiayun (NASDAQ：RTC) announced that the company had signed a series of important agreements with YA II PN, Ltd, a fund managed by Yorkville Advisors Global and LP. The company received $15 million in financing, and the down payment of $3 million was received on the signing date of the agreement.Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.